TW201713342A - 以吡嗪羧醯胺化合物為有效成分之醫藥組成物 - Google Patents
以吡嗪羧醯胺化合物為有效成分之醫藥組成物 Download PDFInfo
- Publication number
- TW201713342A TW201713342A TW105113124A TW105113124A TW201713342A TW 201713342 A TW201713342 A TW 201713342A TW 105113124 A TW105113124 A TW 105113124A TW 105113124 A TW105113124 A TW 105113124A TW 201713342 A TW201713342 A TW 201713342A
- Authority
- TW
- Taiwan
- Prior art keywords
- bmx
- cancer
- compound
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015092301A JP2018104290A (ja) | 2015-04-28 | 2015-04-28 | ピラジンカルボキサミド化合物を有効成分とする医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201713342A true TW201713342A (zh) | 2017-04-16 |
Family
ID=57198305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW105113124A TW201713342A (zh) | 2015-04-28 | 2016-04-27 | 以吡嗪羧醯胺化合物為有效成分之醫藥組成物 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2018104290A (ja) |
TW (1) | TW201713342A (ja) |
WO (1) | WO2016175252A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019014653A (ja) * | 2015-11-27 | 2019-01-31 | アステラス製薬株式会社 | がん免疫を介したがん治療方法 |
US20190282569A1 (en) | 2016-10-26 | 2019-09-19 | Astellas Pharma Inc. | Stable pharmaceutical composition |
TW202340177A (zh) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | 作為 flt3抑制劑之吡嗪化合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX360970B (es) * | 2008-06-27 | 2018-11-23 | Avila Therapeutics Inc | Compuestos de heteroarilo y usos de los mismos. |
AR089727A1 (es) * | 2012-01-17 | 2014-09-10 | Astellas Pharma Inc | Compuesto de pirazin-carboxamida |
ES2618007T3 (es) * | 2012-08-06 | 2017-06-20 | Acea Biosciences, Inc. | Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas |
-
2015
- 2015-04-28 JP JP2015092301A patent/JP2018104290A/ja active Pending
-
2016
- 2016-04-27 WO PCT/JP2016/063246 patent/WO2016175252A1/ja active Application Filing
- 2016-04-27 TW TW105113124A patent/TW201713342A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016175252A1 (ja) | 2016-11-03 |
JP2018104290A (ja) | 2018-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2694072T3 (en) | COMBINATION OF ACT-INHIBITOR RELATIONSHIP AND ABIRATERON FOR USE IN THERAPEUTIC TREATMENTS | |
TWI333953B (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
US20190111058A1 (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
JP2021535146A (ja) | Cxcr4阻害剤の組成物ならびに調製および使用の方法 | |
TWI656875B (zh) | 藉二氫吡并吡治療癌症 | |
US11311552B2 (en) | Therapies for cancer | |
TW201242598A (en) | Combination therapies for hematologic malignancies | |
TWI655945B (zh) | 以二胺基雜環羧醯胺化合物作爲有效成分之醫藥組成物 | |
JP2021176819A (ja) | キナゾリン化合物を有効成分とする医薬組成物 | |
CN102647906A (zh) | 三环化合物及其药学用途 | |
CN105461694A (zh) | 取代的杂芳基化合物及其组合物和用途 | |
TW201526894A (zh) | 藉二氫吡并吡治療癌症 | |
NZ579945A (en) | Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
TW201605454A (zh) | 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 | |
TW201713342A (zh) | 以吡嗪羧醯胺化合物為有效成分之醫藥組成物 | |
WO2017205756A1 (en) | 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in therapy-resistant cancer cells | |
KR20170046193A (ko) | 감소된 brca2 활성을 갖는 암 대상자의 치료를 위한 sns-595의 사용 방법 | |
TW201625254A (zh) | 以吡羧醯胺化合物作為有效成分之醫藥組成物 | |
US20210179591A1 (en) | New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors | |
JP2017521468A (ja) | 組み合わせ療法 | |
US20180263979A1 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
WO2016029002A2 (en) | Growth factor receptor inhibitors | |
JP2020514345A (ja) | 新規な癌の治療法 | |
US20230000876A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
WO2023202563A1 (en) | Akt inhibitor in combination with pim kinase inhibitor |